Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53 - PubMed (original) (raw)

Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53

N C Reich et al. Mol Cell Biol. 1983 Dec.

Abstract

The steady-state levels of p53 protein and p53 mRNA in transformed and nontransformed cells were examined to elucidate the mechanisms controlling expression of p53. mRNA levels were determined by Northern blot hybridization analysis, employing a p53-specific cDNA clone (M. Oren and A.J. Levine, Proc. Natl. Acad. Sci. U.S.A. 80:56-59, 1983), and protein levels were determined by the Western blotting technique. Analysis of p53 mRNA revealed a single polyadenylated mRNA species migrating at ca. 18S. Levels of p53 mRNA in simian virus 40-transformed cell line (SVT2) and in an homologous nontransformed cell line (3T3) were equivalent, although the steady-state levels of p53 protein were 25- to 100-fold higher in the SVT2 cells than in the 3T3 cells. A study with a non-virus-transformed cell system revealed a different result. Embryonal carcinoma cells (F9) were found to have nearly 20-fold higher levels of p53 mRNA in comparison with differentiated benign progeny cells. In this system the difference in p53 mRNA levels corresponded to the difference in p53 protein levels. Pulse-chase experiments were performed to study the half-life of p53 protein in these four types of cells. The turnover of p53 protein occurred with biphasic kinetics. In addition, it was found that protein synthesis inhibitors placed in the medium during the chase period prevented the turnover of p53 protein in transformed cells, but not in nontransformed (3T3) cells. These results provide evidence that the regulation of p53 expression in cells can occur at the level of p53 mRNA abundancy or p53 protein stability depending upon the experimental system under study, and that a regulated degradation process controls the turnover of p53 protein.

PubMed Disclaimer

Cited by

Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.
Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM. Scheffner M, et al. J Virol. 1992 Aug;66(8):5100-5. doi: 10.1128/JVI.66.8.5100-5105.1992. J Virol. 1992. PMID: 1321290 Free PMC article.
P53 accumulation in precursor lesions and early stages of bladder cancer.
Schmitz-Dräger BJ, van Roeyen CR, Grimm MO, Gerharz CD, Decken K, Schulz WA, Bültel H, Makri D, Ebert T, Ackermann R. Schmitz-Dräger BJ, et al. World J Urol. 1994;12(2):79-83. doi: 10.1007/BF00184241. World J Urol. 1994. PMID: 8087143
Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.
Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M. Gottlieb E, et al. EMBO J. 1997 Mar 17;16(6):1381-90. doi: 10.1093/emboj/16.6.1381. EMBO J. 1997. PMID: 9135153 Free PMC article.
Regulation of GAD65 expression by SMAR1 and p53 upon Streptozotocin treatment.
Singh S, Raina V, Chavali PL, Dubash T, Kadreppa S, Parab P, Chattopadhyay S. Singh S, et al. BMC Mol Biol. 2012 Sep 14;13:28. doi: 10.1186/1471-2199-13-28. BMC Mol Biol. 2012. PMID: 22978699 Free PMC article.
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.
Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Finlay CA, et al. Mol Cell Biol. 1988 Feb;8(2):531-9. doi: 10.1128/mcb.8.2.531-539.1988. Mol Cell Biol. 1988. PMID: 2832726 Free PMC article.

References

1. J Cell Physiol. 1968 Oct;72(2):141-8 - PubMed
1. Biochemistry. 1977 Oct 18;16(21):4743-51 - PubMed
1. Nature. 1979 Mar 15;278(5701):261-3 - PubMed
1. Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4 - PubMed
1. Cell. 1979 May;17(1):43-52 - PubMed

Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53 - PubMed (original) (raw)